India Pharma Outlook Team | Wednesday, 06 August 2025
According to Orchid Pharma, the Court of France has issued an order in favor of the company, allowing it to purchase Allecra Therapeutics SAS's assets as of August 1, 2025. The company announced on July 30, 2025, that it had signed an agreement with Allecra Therapeutics GmbH's (Germany) insolvency administrator to buy all of Allecra Therapeutics GmbH's (Germany) assets, including intellectual property, trademarks, customer contracts, regulatory filings, and tangible and intangible assets.
The company's binding bid, submitted in conjunction with Allecra Therapeutics SAS's insolvency administrator, was accepted by the French court during the July 30 hearing for the purchase of Allecra Therapeutics SAS's intellectual property rights and trademarks. Within a few time, the official declaration of order was to be issued."We are hopeful to get the order in our favour, Orchid Pharma had said in a statement.
The business announced in a post-trading report yesterday that the Court of France had rendered an order in favor of Orchid Pharma. Following this transaction, Orchid Pharma has consolidated rights and control formerly divided among entities to acquire 100% worldwide ownership of Enmetazobactam (International Brand Name known as EXBLIFEP; Orblicef in India).
Also Read: Emcure Joins Hands with Sanofi to Boost Diabetes Drug Access in India
The first new antibiotic molecule found in India would then be fully repatriated to India. According to Orchid Pharma, "Orchid Brand will grow and expand globally as a result of this consolidation through smart asset purchases, and the company will benefit financially." One of the top pharmaceutical businesses in India, Orchid Pharma is based in Chennai and develops, produces, and markets a variety of bulk actives, formulations, and nutraceuticals. It exports to more than 40 countries.
